Loading
companiesCompany
Juventas Cell Therapy
Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).
Also called: Hebei Senlang Biotechnology
Overview
Juventas Cell Therapy was founded in Tianjin with the Chinese Academy of Medical Sciences Institute of Hematology. Its CD19 CAR-T inaticabtagene autoleucel (CNCT19) was approved by the NMPA in November 2023 for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, and is also in trials for large B-cell lymphoma.
Headquarters
Tianjin, China, CN
Scorecard
All companies#287of 1244 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedCell therapy (autologous CD19 CAR-T)
Inaticabtagene autoleucel · Yuanruida
Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023.
Similar pages
- InstitutionInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shares Inaticabtagene autoleucel, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag china.
- CompanyIASO Biotherapeutics
Shares CAR-T cell therapy and the tag china.
- PersonXiaojun Huang
Shares Acute lymphoblastic leukaemia and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CAR-T cell therapy and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- TrialFUMANBA-1
Shares CAR-T cell therapy and the tag china.
- TrialRELIANCE
Shares CAR-T cell therapy and the tag china.
cancers
technologies
drugs
ApprovedCell therapy (autologous CD19 CAR-T)
Inaticabtagene autoleucel · Yuanruida
trials
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic LeukemiaPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma